Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)
Repligen Analyst Ratings
RBC Capital Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $205
Craig-Hallum Maintains Repligen(RGEN.US) With Buy Rating
Craig-Hallum Sticks to Their Buy Rating for Repligen (RGEN)
Wells Fargo Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $180
Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA) and Repligen (RGEN)
Wells Fargo Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $180
Jefferies Upgrades Repligen(RGEN.US) to Buy Rating, Raises Target Price to $180
Repligen Analyst Ratings
Buy Rating Affirmed: Overlooked Long-Term Benefits of Repligen's Potential Maravai Acquisition
Jefferies Maintains Repligen(RGEN.US) With Hold Rating, Cuts Target Price to $160
Jefferies Remains a Hold on Repligen (RGEN)
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA), Repligen (RGEN) and Teva Pharmaceutical (TEVA)
Repligen Analyst Ratings
Buy Rating Reaffirmed for Repligen Amid Strong Growth Prospects and Market Resilience
Repligen Price Target Cut to $185.00/Share From $205.00 by UBS
RBC Capital Reiterates Outperform on Repligen, Maintains $190 Price Target
Craig-Hallum Maintains Repligen(RGEN.US) With Buy Rating, Announces Target Price $225
Deutsche Bank Adjusts Repligen Price Target to $175 From $155, Maintains Buy Rating